SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-005364 to VERU INC. (VERU)

VERU INC.
Date: May 19, 2023 · CIK: 0000863894 · Accession: 0000000000-23-005364

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-271891

Date
May 19, 2023
Author
Mitchell Steiner, M.D.
Form
UPLOAD
Company
VERU INC.

Letter

United States securities and exchange commission logo May 19, 2023 Mitchell Steiner, M.D. Chief Executive Officer Veru Inc. 2916 N. Miami Avenue Suite 1000 Miami, Florida 33127 Re:Veru Inc. Registration Statement on Form S-3 Filed May 12, 2023 File No. 333-271891 Dear Mitchell Steiner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Benjamin G. Lombard

Show Raw Text
United States securities and exchange commission logo
May 19, 2023
Mitchell Steiner, M.D.
Chief Executive Officer
Veru Inc.
2916 N. Miami Avenue
Suite 1000
Miami, Florida 33127
Re:Veru Inc.
Registration Statement on Form S-3
Filed May 12, 2023
File No. 333-271891
Dear Mitchell Steiner:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Benjamin G. Lombard